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Abstract 
This review article focuses on the current local therapies mediated by implanted macroscaled 
biomaterials available or proposed for fighting cancer and also highlights the upcoming 
research in this field. Several authoritative review articles have collected and discussed the 
state-of-the-art as well as the advancements in using biomaterial-based micro- and nano-
particle systems for drug delivery in cancer therapy. On the other hand, implantable 
biomaterial devices are emerging as highly versatile therapeutic platforms, which deserve an 
increased attention by the healthcare scientific community, as they are able to offer innovative, 
more effective and creative strategies against tumors. This review summarizes the current 
approaches which exploit biomaterial-based devices as implantable tools for locally 
administrating drugs and describes their specific medical applications, which mainly target 
resected brain tumors or their metastases for the inaccessibility of conventional 
chemotherapies. Moreover, a special focus in this review is given to innovative approaches, 
Revised Manuscript
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such as combined delivery therapies, as well as to alternative approaches, such as scaffolds 
for gene therapy, cancer immunotherapy and metastatic cell capture, the later as promising 
future trends in implantable biomaterials for cancer applications.  
 
1. Introduction 
Cancer, also known as malignant tumor or neoplasm, accounts for a large number of diseases 
in which the cells have undergone mutations in their genetic material leading to uncontrolled 
growth. Cancer affects people of all ages, sex, social status and ethnicity and second to 
cardiovascular diseases, is the leading primary cause of illness-related death in the world, 
resulting in 8.2 million death in 2012.[1] There were 14 million new cancer cases in 2012 and 
this number is expected to rise to 22 million within the next two decades. The growing impact 
of cancer on global health and the dismal prognosis for patients, including large mortality 
rates, poor quality of life and high costs for therapy, have resulted in this pathology being 
labelled as a societal challenge for this century. There is a continuously ongoing search for 
improved or novel treatments to fight this deadly disease. Systemic delivery of anti-neoplastic 
agents, which can inhibit or halt the progression of tumors, such as chemotherapy or anti-
angiogenic drugs, has long been one of the traditional methods of treating cancer. A number 
of technologies have been used and investigated to fight cancer systemically such as 
chemotherapy administered via oral capsules, injections of nano/microparticles; 
immunotherapy, administrated via engineered cell infusion. However even with these 
technologies, there still remain many shortcomings associated with systemic delivery, 
including low local drug concentration at the targeted tumor site, non-target cell and organ 
toxicity as well as low efficacy of the delivered drug due to its short half-life. The modest 
success and toxicity associated with current systemic delivery of drugs has motivated 
researchers to find a more direct approach to deliver agents for cancer therapy.  
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Local therapy systems, delivering the drugs directly to the targeted site of interest via 
an implantable system, are a promising alternative to systemic delivery. Local delivery 
systems are usually designed to be implanted immediately after a tumor debunking surgery, 
which omit the need of performing an additional surgery to place the therapeutic material in 
the patient. By delivering drugs topically, the pharmaceutical concentration at the tumor 
environment can be maximized, non-target systemic exposure and organ toxicity can be 
minimized and the need of finding a method to cross the blood brain barrier (BBB) for brain 
cancer treatments can be avoided. Furthermore, on-site delivery can increase the efficacy of 
the drug by bypassing the harsh environment and longer journey that the drug has to take to 
reach the site of interest when delivered systemically. Usually, the development of new drugs 
is associated with high cost and time consuming research efforts. Thus, it would be beneficial 
if new treatment methods are designed to successfully deliver currently available therapeutic 
agents. In fact, many of them have been shown to be promising in vitro however failed or 
resulted in modest outcomes when delivered in vivo systemically due to the barriers 
associated with this delivery method. Optimally designed implantable devices that can locally 
deliver already available and clinically-tested drugs may be an intelligent solution to 
repurpose promising drugs for cancer treatment.  
 Common implantable devices used for cancer therapy refer to subcutaneous ports for 
systemic drug infusion. A port, also known as a port-a-cath, is a totally implantable drug 
dispensing system composed of a small reservoir, refillable through periodic injections, made 
by a metal holder and a silicon membrane, which is placed subcutaneously and connected to a 
catheter that delivers the drug directly into the blood stream through an implanted needle. 
These devices need to be refilled periodically during therapy, washed to prevent occlusion, 
and finally removed by surgery, thus carrying the risks for infections and thrombosis. On the 
other hand, biomaterial-based implantable devices are non-hydraulic drug delivery systems 
where the biomaterial is the key enabler for a local therapy. Owing to the tailorability of 
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biomaterials, these devices can release multiple drugs and catalyze cellular reactions over 
different time-scales, and be designed to be resorbed instead of surgically explanted after a 
certain time. Some biomaterial devices are able to self-assemble upon injection, thus also 
avoiding the need for a surgical procedure to implant the device. Moreover, the risk for 
thrombosis and infections associated with these devices are low as they are not intravenous 
systems with no percutaneous access.  
Over the years, the field of biomaterials has emerged to become a useful tool to better 
study cancer in vitro (e.g. 3D culture as an intermediate stage between 2D culture and animal 
models),[2, 3] for diagnostic applications (e.g. biomaterials-based immunoassay to detect 
biomarkers),[4, 5] for imaging (e.g. biomaterials to facilitate the delivery of contrast agents),[6] 
as well as for the advancement of therapies for this disease (e.g. biomaterials to assist in drug 
targeting and delivery).[7, 8] Biomaterial properties such as their size, shape, charge, surface 
chemistry, morphology and physiochemical properties can easily be tailored,[9] and thus, can 
be used to tackle the specific challenges in malignancies and thus, can serve as a useful 
innovative tool to improve the current technologies available for cancer diagnostic, imaging 
and therapeutics.  
In this review, we focused on highlighting the biomaterials-based implantable devices 
that have been developed for cancer therapy. Biomaterials in the form of nanoparticles,[10] 
microparticles,[11] liposomes,[12] dendrimers,[13] and nanotubes,[14] have often been used to 
improve the systemic delivery of therapeutics such as drugs or genes for the treatment of 
cancer which have been address by many distinguished review papers,[15-18] and thus, are 
beyond the scope of this review article. Such particle-based systems have also been used to 
deliver drug locally to the site of interest. Although the administration of drug systemically 
mediated by these types of biomaterials is able to overcome some of the barriers of delivery, 
these particulate systems are still unable to overcome many of the challenges associated with 
systemic delivery including low local drug concentration at the targeted tumor site, non-target 
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cell and organ toxicity as well as low efficacy of the delivered drug due to its short half-life. 
The delivery of therapeutics locally with these types of biomaterials will not be as easily 
retained at the site of interest due to their small size. Implantable drug devices may be a 
promising alternative to overcome the drawbacks of other delivery systems whose action is 
not or cannot stay confined within a specific target area. Moreover, the use of implantable 
biomaterial devices has recently been demonstrated as an intriguing and versatile component 
for innovative cancer therapies different from mere drug delivery, thus appearing as next 
generation tools for multifunctional cancer treatments. 
 Various non-biodegradable [ethylene-vinyl acetate copolymer (EVAc)][19-22] as well as 
biodegradable materials [e.g. polyanhydride poly[bis(p-carboxy-phenoxy)propane-sebacic 
acid] copolymer (p(CPP:SA))],[7, 23-32] fatty acid dimer–sebacic acid copolymer (FAD-SA),[33] 
poly(lactic-co-glycolic acid) copolymer (PLGA)[34-38] and poly-ϵ-caprolactone (PCL)[39-41] 
have been investigated for the local delivery of different cancer therapeutic agents including 
chemotherapy drugs [e.g. paclitaxel, doxorubicin, bis-chloroethylnitrosourea (BCNU)] and 
anti-angiogenic factors such as minocycline,[8, 22, 23] and endostatin fragment.[29] The 
implantable materials can be in different forms including wafers, discs, films, rods or meshes 
and can be fabricated by different methods such as electrospinning, solvent casting, extrusion 
or compression molding. An overview of these biomaterials-based local delivery devices for 
cancer treatments is given in Table 1. 
Besides the delivery of a chemotherapy drug alone, local delivery systems can also be 
used for other applications such as for the delivery of a combination of chemotherapy drugs 
(known as poly-chemotherapy) or concurrent delivery of a chemotherapy and an anti-
angiogenic factor. These implantable scaffolds can also be used to delivery genes instead of 
only drugs. Some groups have also started developing scaffold systems for immunotherapy 
applications in which engineered immune cells, monoclonal antibodies, and/or immune 
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checkpoint inhibitors are loaded into the devices to act as cell delivery systems or vaccine 
sites. All these alternative applications to single chemotherapy delivery within implantable 
devices represent future biomaterial-based trends for novel and more effective cancer 
therapies (Table 1).  
This review article aims at summarizing and discussing the state-of-the-art of 
implantable biomaterial devices as innovative tools for cancer treatment in order to provide a 
comprehensive and influential scientific base supporting future strategic directions in cancer 
therapies. This review begins by discussing the targets of localized cancer therapy in Section 
2 which includes an emphasis of targeting resected primary gliomas and intracranial 
metastases. The biomaterial-based implantable devices for the delivery of chemotherapy is 
then discussed in Section 3, followed by a review of other applications of implantable 
biomaterial devices for cancer therapy. Specifically, Section 4 focuses on combinational 
therapies where local delivery of a chemotherapy or anti-angiogenic agent is combined with 
radiotherapy, or local delivery of an anti-angiogenic agent is combined with systemic 
chemotherapy. The review ends with a discussion of future applications of implantable 
biomaterial devices for cancer therapy in Section 5, which includes the local delivery of both 
an anti-angiogenic and chemotherapy drug, poly-chemotherapy, gene therapy, 
immunotherapy and biomaterial polymer composites.  
 
 
2. Targets of Localized Cancer Therapy 
2.1. Resected Primary Gliomas 
Brain cancer is mostly common during childhood and later in old age.[42] Around 
14,000 people are annually diagnosed with brain cancer,[42] and most of them do not survive 
past 2 to 5 years after being diagnosed with this malignancy.[36] Among primary brain tumors, 
gliomas are the most widespread, with glioblastoma multiforme (GBM) being their most 
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malignant and common high-grade form.[43] GBM is associated with a median survival of 
about 14 months.[43-46] Gliomas are usually treated by resection surgery and external beam 
radiation and sometimes by systemic chemotherapy or a combination of these methods.[31] 
Following resection surgery, tumor recurrence can occur due to the infiltrative nature of the 
malignant gliomas,[47] which are usually within 2 cm of the original lesion.[48] Thus, following 
tumor resection surgery, systemic chemotherapy treatment is often given to patients as an 
adjuvant therapy. However, for brain cancer, systemic delivery is not efficient as many of the 
drugs are usually excluded from the central nervous system (CNS) due to the BBB.[49] 
Although some chemotherapy agents, such as the classes of anti-proliferation alkylating 
agents temozolomide and nitrosoureas bis-chloroethylnitrosourea (BCNU) and lomustine, are 
able to cross the BBB at some extent and have been used clinically,[50] the efficacy of these 
drugs even as a concurrent treatment with radiotherapy has revealed to be modest.[51, 52] The 
insufficient improvement in patients’ prognosis with current drugs is partly due to an 
inadequate delivery: their low local concentrations may prevent them to be really effective at 
the targeted sites.[53, 54] Furthermore, the short half-life (e.g., about 15-20 min for BCNU) and 
systemic toxicities are also problems associated with systemic delivery of these drugs.[31] 
Different methods have been investigated and employed to improve the delivery of 
drugs across the BBB such as hydrophobic side group modification, conjugation to ligands 
with known BBB carriers like transferrin, or delivery with biomaterials such as liposomes or 
nano-particles.[55] Unfortunately, none of these approaches have been clinically successful in 
the treatment of glioma. This has led researchers to discover methods to deliver drugs directly 
at the targeted site to avoid the challenges of systemic delivery. Specifically, the devices are 
designed to be implanted during a resection surgery of primary gliomas as an adjuvant 
therapy. The outcome of implantable drug delivery devices may be different when used for a 
primary versus recurrent surgery in terms of the clinical benefit and safety profile. Tumor 
cells after recurrence tumor resection may not be as assessable due to gliosis and may prevent 
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diffusion of the drug into the brain parenchyma.[31] Thus, these devices are usually developed 
for primary and not for recurrence tumor resections. 
Frazier et al. showed that in their rat intracranial tumor model, resection was not 
necessary to achieve significant increase in median survival time when the anti-angiogenesis 
drug minocycline was delivered locally with or without systemic BCNU (100% and 200% 
increase compared to no treatment, respectively).[8] However, owing to the limit in drug 
penetration experienced with unresected primary tumors, more focus is placed on applying 
local delivery of agents for resected sites. 
 
2.2. Resected Intracranial Metastases 
Brain metastases represent a frequent complication of cancers and are actually more 
common than primary brain tumors.[56] Around 20%-40% of patients affected by malignant 
neoplasms suffer from brain metastases. About 170,000 patients are diagnosed with brain 
metastases each year in the US which is more than 10-fold higher than those diagnosed with 
primary brain malignancy.[57-59] Lung cancer (minimum 50%), breast cancer (15%-25%) and 
melanoma (5%-20%) are the most common cancer associated with brain metastases. These 
metastatic brain lesions usually develop late, after extracranial metastatic sites. Despite 
advances in treating brain metastases, the median survival is only 7-16 months.[60-63] Novel 
types of therapy are thus vital to cure and prolong survival of patients with brain metastases. 
Furthermore, adjuvant treatment is needed by patients whose overall survival cannot be 
prolonged, however, can benefit from palliative care to relief neurological symptoms.[64, 65]  
For multiple brain lesions (four or more), brain metastases are mostly treated with 
whole-brain radiotherapy (WBRT). Alternatively, for up to three lesions, a surgical approach 
is still used to remove the lesions prior to radiotherapy. Nonetheless, recurrence tends to occur 
due to microscopic-infiltrative tumor left behind after the surgery as the surgeon tries to avoid 
the risk of causing neurologic dysfunction.[66] Chemotherapy is not usually applied to treat 
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brain metastases and only considered after the other methods, (i.e. surgery, WBRT and 
stereotactic radiosurgery) have been exhausted.[43] This is because chemotherapy is usually 
ineffective as the BBB prevents the drugs to be administered to the lesions. Local control of 
recurrence with an implantable device may be a promising strategy as an adjuvant therapy to 
compliment surgical resection for brain metastases. Ewend et al. have developed p(CPP:SA) 
copolymer wafers loaded with chemotherapy agents (i.e. BCNU, carboplatin or camptothecin) 
for the treatment of brain metastases from breast cancer[7] and colon, renal and lung cancer 
and melanoma.[26] These local delivery systems were implanted and tested with or without 
external beam radiotherapy. 
 
2.3. Other Types of Cancer 
Due to the challenge of having to cross the BBB, a lot of the research being performed 
on biomaterials-based local delivery systems for cancer treatment have been focused on 
combating brain cancer either as an adjuvant therapy for primary malignant gliomas or 
metastatic intracranial tumors. However, besides the treatment of primary malignant gliomas 
and brain metastases, local delivery systems have also been developed and investigated for 
the treatment of other malignancies. Keskar et al. studied the delivery of cisplatin for the 
treatment of cervical cancer.[19] Cervical cancer is the second most common cancer among 
women worldwide. It is the leading cause of death from cancer among women in developing 
countries with an estimated death of 274,000.[67] Local delivery is a promising treatment 
method for cervical cancer because of the easy accessibility of the tumor due to the location 
of the cervix. Keskar et al. modeled the cisplatin local delivery device on currently available 
ring-based-intra-vaginal devices that are available for contraception. The great advantage of 
this device compared to other local delivery systems developed for other malignancies is that 
this device can be easily inserted and replaced by the patients themselves. 
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 Liu et al. investigated local delivery as an adjuvant therapy for sarcoma.[68] 
Locoregional recurrence of sarcoma often occurs in the abdomen, pelvic and retroperitoneum 
after macroscopically complete resections. The currently available conventional adjuvant 
therapies such as systemic chemotherapy, single-dose hyperthermic intraperitoneal 
chemotherapy (HIPEC) and radiation have not revealed to be very beneficial. Local delivery 
of chemotherapy may be a potential option to replace these current adjuvant therapies. Liu et 
al. showed that the delivery of paclitaxel from a poly(glycerol monostearate-co-ε-
caprolactone) polymer film can reduce locoregional recurrence rate and improve overall 
survival. 
 Local delivery devices have also been developed recently to combat lung cancer. 
Wolinsky et al. designed a drug eluting polymeric device for the delivery of a potent 
anticancer agent, 10-hydroxycamptothecin (HCPT), for the treatment of lung cancer.[69] Due 
to the limited pulmonary reserve, lung cancer patients often are susceptible to local tumor 
recurrence following primary treatment. The device developed by Wolinsky et al. 
successfully prevented local growth of malignant cells in vivo. Liu et al. used the same 
polymeric material to deliver paclitaxel for the treatment of non-small cell lung cancer 
(NSCLC) to prevent local tumor recurrence.[70] Other cancer types in which biomaterial-based 
devices show promising applications include leukemia and melanoma, under immunotherapy 
applications, which are discussed in section 5.4. A detailed discussion of the different types of 
biomaterials that have been used to develop implantable devices for local delivery of 
chemotherapy is presented in the next section. 
 
3. Materials Used as Implantable Devices for Local Delivery of Chemotherapy 
Both non-biodegradable and biodegradable materials have been used to develop 
implantable devices as local delivery systems for cancer therapy. For non-biodegradable 
materials, the release of the drug is usually administered by diffusion through the polymer 
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matrix which is driven by the concentration gradient of the drug in the solid. The diffusion 
rate of the drug will also depend on its solubility in the polymer matrix and surrounding 
medium, diffusion coefficient, molecular weight, concentration throughout the polymer 
matrix and the distance necessary for the drug to diffuse. As for biodegradable materials, the 
release of the drug is not only governed by diffusion but also on the erosion of the polymer 
matrix and thus, there are more options to control the release kinetics of the drug from these 
types of materials. Erosion occurs through physical dissolution of the polymer matrix by 
degradation. Biodegradable polymers are usually designed to degrade by hydrolysis or 
enzymatically. Degradation can occur through surface erosion, in which any contact between 
material and water is confined at the surface of the material causing polymer chain scission 
only at its surface, or through bulk erosion, in which water penetrates the bulk polymer 
causing erosion of the entire material. For both biostable and biodegradable materials, the 
early stage of release is often diffusion-controlled as there is a burst release of drugs adsorbed 
on the surface or entrapped near the surface of the matrix. This burst release is then often 
followed by the sustained release of the drug through erosion or further diffusion of the drug 
entrapped in the matrix. Although capable of successfully delivering intact drug in a 
controlled manner, the application of non-biodegradable materials is limited as it is more 
suitable for applications where the device will be removed in the future and thus, the long-
term response of the body to the implant left at the site will not be a concern. 
 
3.1. Ethylene-Vinyl Acetate Copolymer (EVAc) 
Ethylene-vinyl acetate copolymer (EVAc) is a non-biodegradable material that has 
been used clinically for birth control applications,[71] as well as for the treatment of 
glaucoma.[72] This material has been shown previously to be non-inflammatory in a rabbit 
cornea assay.[73] Since EVAc is non-degradable, the release kinetics are based on diffusion 
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alone and not on the erosion of the material and thus, can easily be studied. However, because 
it does not degrade, the device will remain as a permanent implant. 
EVAc disc or cylinders are usually fabricated by solvent casting. Yang et al. designed 
local delivery devices loaded with of Bis-chloroethylnitrosourea, (BCNU, also known as 
carmustine) from EVAc discs to avoid toxicity associated with systemic delivery and to 
increase local concentration of the drug for the treatment of localized brain tumors.[74] BCNU 
is an alkylating agent used for chemotherapy that has a very short half-life of about 15-20 min 
in vivo.[75] Compared to other drugs, BCNU is actually capable of penetrating the BBB to a 
certain extent due to its good liposolubility and low molecular weight.[76] However, the high 
systemic toxicity and short half-life of this drug makes it a good candidate that will benefit 
significantly from being incorporated inside an implantable system. The implantable device 
was fabricated by dissolving the drug and polymer in methylene chloride and the solution was 
then pipetted into cooled glass cylindrical molds. After evaporating the solvent, the cylinders 
were cut to desired weight. Yang et al. determined that the implantable discs were able to 
control the release of intact BCNU both in vitro and in vivo.[74] Furthermore, discs implanted 
in a rat intracranial model resulted in significantly higher concentration of the drug to the 
implanted hemisphere and lower levels in the peripheral circulation compared to the systemic 
delivery of the drug. Two other groups have also studied applications of this material to 
deliver the chemotherapy drugs amsacrine (Brand name: Amsidine®)[21] and mitoxantrone 
(Brand name: Novantrone)[20] to rat intracranial glioma models and found that their delivery 
from EVAc discs had potential anti-tumor effects in vivo.  
 Keskar et al. investigated the delivery of cisplatin from an EVAc device for the 
treatment of cervical cancer.[19] This biomaterial implantable device was fabricated using a 
similar method as Yang et al.;[74] however, with Teflon molds instead of glass molds. As 
shown in Figure 1, the cisplatin crystals were uniformly dispersed in the EVAc scaffold, 
resulting in two distinct phases of the polymer matrix and cisplatin crystal. In vitro studies 
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showed that the device was effective against both HPV positive and negative cervical cancer 
cell lines. 
 
3.2. Polyanhydride Poly[bis(p-Carboxy-Phenoxy)Propane-Sebacic Acid] Copolymer 
(p(CPP:SA)) 
Polyanhydride poly[bis(p-carboxy-phenoxy)propane-sebacic acid] copolymer 
(p(CPP:SA)) is a material that has been used widely for the delivery of cancer drugs in a form 
of an implantable device. The biocompatibility of this material has been widely tested and 
found to be non-toxic.[30] The degradation rate of this polymer can be controlled by the ratio 
of the PCCP and SA monomers in the polymer, which provides versatility in controlling the 
release of the drug encapsulated. The delivery systems are usually prepared by dissolving the 
drug and copolymer in methylene chloride followed by evaporation of the solvent, which is 
usually performed in vacuum desiccators or under a nitrogen stream.[30] A dried powder is 
obtained through this process and then processed via compression-molding into wafers/discs. 
Among the implantable devices made from this material that have been investigated thus far, 
Gliadel®, a commercial implant which is made out of p(CPP:SA), so far is the most advanced 
biomaterial studied for the treatment of brain gliomas (Figure 2). Gliadel® is a p(CPP:SA) 
20:80 wafer (14 mm diameter × 1 mm thickness, and loaded with 7.7 mg of drug)[31, 77, 78] that 
is designed to release BCNU over a 2-3 week period.[79] It has been approved by the U.S. 
Federal Food and Drug Administration (FDA) for the treatment of new diagnosis of high 
grade malignant glioma in addition to surgery and radiation, as well as for the treatment of 
recurrent GBM in addition to surgery. There are many studies that have investigated the 
benefit of Gliadel® wafers for malignant glioma.[24, 31, 80-84] Although a promising device, O6-
Alklyguanine-DNA alkyltransferase (AGT), a DNA-repair protein found in the majority of 
brain tumors results in resistance to BCNU. As a consequence, Gliadel® is only useful in a 
very limited number of patients.[85]  
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Other drugs and biomolecules have also been loaded into p(CPP:SA) wafers for the 
treatment of malignant gliomas: taxol (Paclitaxel),[30] mitoxantrone,[25] doxorubicin (DOX),[86] 
carboplatin,[28] and interleukin-2 (IL-2) in combination with Adriamycin (ADR).[27] Lesniak et 
al. investigated the delivery of DOX from p(CPP:SA) wafers.[86] Animals treated with DOX 
resulted in decreased tumor burden and tissue necrosis within the tumor and in the 
surrounding brain (Figure 3). More recently, Wicks et al. investigated the delivery of cancer-
cell glycolytic inhibitors 3-bromopyruvate (3-BrPA) and dichloroacetate (DCA) with 
pCPP:SA wafers both by themselves or in combination with the chemotherapy drug 
temozolomide (TMZ) and radiation therapy (XRT).[32] They found that the delivery of 5% 3-
BrPA wafer and temozolomide produced a synergistic effect compared to either therapy alone. 
The treatment with 5% 3-BrPA wafer in combination with both TMZ and XRT (triple 
combination) did not result in a statistical advantage in survival compared with the 
combination therapy of TMZ and XRT. However, the triple combination therapy (5% 3-BrPA 
wafer given on day 0 in combination with TMZ and XRT) did result in long-term 
survivorship of 30%. 
In addition to being tested as an implantable device for adjuvant therapy at the primary 
glioma tumor site following resection surgery, p(CPP:SA) wafers have also been designed by 
Ewend et al. for the treatment of intracranial metastases existing from various types of 
cancer.[7, 26] Three different chemotherapy agents were loaded into the p(CPP:SA) wafers (1.5 
mm diameter × 0.5 mm height, 5 mg in weight, 0.5%, 1%, 10%, 20% drug): BCNU, 
carboplatin and camptothecin. They found that the delivery of local chemotherapy alone or in 
combination with radiation was effective in prolonging the lives of mice with intracranial 
metastases for some of the combination of drugs and models (intracranial melanoma, lung 
carcinoma, renal cell carcinoma and colon carcinoma metastases) tested[26]. Overall, they 
highlighted that BCNU was the most effective chemotherapy agent. The same group also 
studied these three chemotherapy drugs in an intracranial EMT-6 breast cancer metastases 
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mouse model and demonstrated that BCNU wafers were able to significantly prolong the 
survival time.[7] 
Hsu et al. investigated the local delivery of Adriamycin (ADR)  from p(CPP:SA) 
scaffolds combined with the injection of interleukin-2 (IL-2) gelatin-chondoroitin 6-sulfate 
microspheres.[27] ADR works by inhibiting topoisomerase II, resulting in blocking of DNA 
and RNA synthesis. In vitro, ADR has been shown to have potent anti-glioma activity;[87] 
however, the effect of systemic ADR has been limited in intracranial tumors. IL-2 is a 
cytokine that function paracrinely to result in an anti-tumor response. In this study, Hsu et al. 
showed that the delivery of IL-2 microspheres locally by injection coupled with ADR loaded 
in the scaffolds were able to prolong survival in an gliosarcoma animal model compared to 
either therapy alone. Besides this study, they have also investigated the delivery of genetically 
engineered tumor cells that produce IL-2 with scaffolds loaded with BCNU or carboplatin,[88] 
and also the combinational delivery of IL-2 microspheres with BCNU loaded p(sCPP:SA) 
scaffolds.[89] 
 
3.3. Fatty Acid Dimer-Sebacic Acid Copolymer (FAD-SA) 
When choosing a biomaterial to be used for controlled delivery of a certain drug, the 
compatibility of the drug and biomaterial is a key parameter that should be considered. The 
p(CCP:SA) wafer revealed to be unsuccessful for the delivery of an innovative drug, 4-
hydroperoxycyclophosphamide (4HC) due to 4HC hydrolytic instability in this copolymer. 
Thus, Judy et al. investigated the use of a copolyanhydride of a fatty acid dimer, erucic acid, 
and sebacic acid (1:1) to deliver 4HC.[33] This alternative polymer, FAD-SA, is able to 
maintain the hydrolytically unstable 4HC in a stable state for local delivery. The delivery of 
4HC drug with the FAD-SA implantable device resulted in higher anti-tumor efficacy 
compared to the delivery of BCNU. 
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3.4. Poly(Lactic-co-Glycolic Acid) (PLGA) 
Poly(lactic-co-glycolic) acid (PLGA), also referred as poly(lactide-co-glycolide) 
(PLG) is an FDA approved copolymer,[90] which is often employed for medical products. This 
material has been used to fabricate drug release vehicles in the form of scaffolds[91-93] and 
microparticles,[94-96] for many different applications, including tissue engineering and 
vaccinations. The degradation rate of PLGA can be tailored by tuning the lactic to glycolic 
acid ratio, molecular weight and the end cap groups of the copolymer. When PLGA is 
exposed to water, hydrolytic degradation of the ester bonds occurs, causing the polymer chain 
to degrade into smaller fragments and eventually yielding lactic and glycolic acid which can 
be metabolized by natural pathways.[97] One of the disadvantages of PLGA is that degradation 
byproducts of the polymer (i.e. lactic and glycolic acid) can cause a decrease in local pH, 
which can result in an inflammatory response and cell death at the implant site. Furthermore, 
the acidic degradation byproducts are associated with the accelerating of autocatalytic 
degradation of the polymer and thus, may result in premature release of encapsulated drug and 
loss of mechanical properties of the scaffold. 
Xie et al. developed electrospun paclitaxel-loaded PLGA ultrafine- and nano-fiber 
implants for the treatment of brain gliomas.[38] The drug and PLGA were dissolved in 
methylene chloride with or without different amount of the organic salt tetrabutylammonium 
tetraphenylborate (TATPB) and electrospun to produce different meshes with fiber diameter 
of around 30 nm to 10 µm. Figure 4 are SEM images of the micro and nanofibers formed. 
Figure S1b and S2b in Figure 4 are images of scaffolds after 61-day of release where most of 
the fibers were broken and melted together due to degradation. The meshes were able to 
sustain the release of the drug for over 60 days. Ranganath et al. have also investigated the 
use of PLGA for the delivery of paclitaxel in malignant gliomas.[37] The paclitaxel-loaded 
PLGA fibrous meshes manufactured via electrospinning were able to sustain the release of 
drug for 80 days. The PLGA implants resulted in much smaller tumors in a mouse 
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subcutaneous C6 glioma in vivo model compared to placebo and Taxol® injected control 
groups. 
 As discussed earlier, BCNU-loaded p(CPP:SA) wafers have been widely studied and 
is currently clinically available as Gliadel® wafers. However, the improvement of survival 
with this implantable device is still modest and thus, further research is needed to find a better 
delivery system for this promising drug. Although the release period of drug from the 
p(CPP:SA) wafers can be increased by increasing the ratio of CPP to SA in the copolymer, 
the maximum duration of release could only reach 18 days (50:50 ratio).[98-101] Seong et al. 
proposed PLGA wafers to deliver BCNU, as this copolymer has a slower degradation rate 
than polyanhydride.[102] BCNU-loaded PLGA microparticles were first prepared by spray-
drying and later used to fabricate wafers by compression molding. Due to the short half-life of 
the drug, the cytotoxic activity of free BCNU powder disappeared within 12 h. When loaded 
into the PLGA wafers, the release of BCNU was prolonged to 8 weeks with cytotoxic activity 
continuing over 1 month. The release of BCNU from these wafers was dependent on 
molecular weight of PLGA, concentration of PLGA in the spray drying polymer solution and 
initial amount of BCNU loaded into the wafers. Lee et al. also prepared BCNU-loaded wafers 
however using a different technique.[34] The drug and PLGA were mixed by vortexing and 
fabricated into wafers by compression molding. These BCNU-loaded PLGA wafers 
significantly inhibited the proliferation of 9L gliosarcoma cells in vitro and delayed the 
growth of the tumor in a subcutaneous rat model compared to the delivery of the powder itself. 
As seen by Seong et al., due to the short half-life of BCNU, its delivery from the wafers 
resulted in higher efficacy and for a longer period than free BCNU powder.[102]   
 PLGA has also been applied in the delivery of doxorubicin for malignant gliomas.[36] 
Doxorubicin is a chemotherapy drug which is well recognized for its safety and has been 
commonly used for patients with disseminated lymphoma or leukemia in the cerebrospinal 
fluid. PLGA and doxorubicin were mixed and dissolved in chloroform and then 
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copolymerized by the solvent-evaporation method. Manome et al. discovered that 3×3 mm 
tetragon sheets implanted into a subcutaneous mice model were completely absorbed after 80 
days. PLGA sheets containing doxorubicin placed next to subcutaneous tumor nodule as 
covering layers significantly inhibited tumor growth compared to the empty sheet controls. 
 PLGA thin films were used to deliver 5-[125I]iodo-2’-deoxyuridine ([125I]IUdR]) to an 
intracranial tumor mice model by Mairs et al.[35] [125I]IUdR] is a thymidine analogue that 
facilitates the delivery of lethal radiation to proliferating cells, and not to quiescent cells. The 
delivery of this radiopharmaceutical locally after resection surgery can be a promising method 
of treatment for residual glioma. [125I]IUdR] was added and incorporated into PLGA by 
sonication and then cast into a small silicon petri-dish. From this study, Mairs and coworkers 
concluded that the release of [125I]IUdR] from an osmotic pump was superior than from the 
biodegradable implant and thus, further studies are needed to achieve a more promising 
delivery of the drug from these films.  
 
3.5. Poly(ε-Caprolactone) (PCL)  
PCL is a biodegradable, biocompatible material that has been widely utilized in many 
biomedical applications. One advantage of PCL is its moldability. This material is often 
electrospun into scaffolds, [103, 104] but it can also be used as a surgical paste. The paste is 
produced by heating PCL at its melting point (50-55°C) followed by injection or topical 
application directly to the tumor resection site, where it will harden up to a solid state at 
physiological temperature.[105] The addition of biological substances such as gelatin, albumin 
and methylcellulose can be applied  to tune the release rate of the drug that is encapsulated in 
this polymer.[41] Due to the comparably low meting point of PCL (10-15°C above 
physiological temperature), thermal damage at the site of implantation is not a concern. 
Methoxypolyethylene glycol (MePEG) can be added to PCL to decrease the melting 
temperature by 5°C.[105] A relevant advantage of PCL being used as an injectable material is 
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the versatility in the shape and size that the material can form. As the exact contour of the 
resection cavity is unpredictable, the PCL-drug injectable implant can easily conform to the 
topography of the site. 
Winternitz et al. studied the delivery of paclitaxel incorporated into surgical paste 
consisting of blends of PCL with MePEG.[105] The in vitro release profile for the drug was 
biphasic, with a burst release lasting 1 or 2 days which was followed by a slow sustained 
release of the drug. The PCL paste discs had anti-angiogenic activity as evaluated with the 
chick chorioallantoic membrane (CAM) assay of angiogenesis. The same system was used to 
deliver an anti-neoplastic drug, bis(maltolato)oxovanadium (BMOV) for the treatment of 
cancer.[39] Jackson et al. successfully showed that the pharmacologic effect was dependent on 
the prolonged exposure of the cells to the drug. The placement of the 5% BMOV-loaded PCL 
at the resected murine radiation-induced fibrosarcoma (RIF-1) tumor site (90% tumor 
resection) prevented tumor regrowth.  
Dordunoo et al. showed that the incorporation of microparticles having co-precipitates 
of paclitaxel/hydrophilic additive (gelatin, albumin and methylcellulose) into the PCL paste 
can increase the in vitro release of the drug.[41] The release of the drug was dependent on the 
type of water-soluble agent, the microparticle size and the proportion of the additives. They 
also showed that the implantation of paclitaxel/gelatin/PCL surgical paste in a subcutaneous 
mouse tumor model resulted in 63% mean tumor regression compared to controls. By 
controlling the release rate of the drug with the addition of water-soluble polymers, the 
efficacy of drug inhibition could be improved. As for PLGA, the disadvantage of PCL is that 
its degradation byproducts are acidic (i.e. caproic acid) and thus, may result in an adverse 
cytotoxic effect at the implant site if the byproducts are release at a high concentration. 
Aimed to investigate alternative surgical paste formulations, Zhang et al. studied the 
release of paclitaxel from PCL combined with other biomedical polymers, namely: (i) 
poly(D,L-lactide)-block-poly(ethylene glycol)-block-poly(D,L-lactide) (PDLLA-PEG-
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PDLLA) copolymers, and (ii) blends of low molecular weight poly(D,L-lactic acid) and poly-
ϵ-caprolactone (PDLLA:PCL).[40] Implantation of molten paste in a subcutaneous 
lymphosarcoma cell (MDAY-D2 tumor cells) mouse model showed that both the paclitaxel 
loaded (PDLLA-PEG-PDLLA) copolymer and 90:10 PDLLA:PCL blend formulations could 
inhibit tumor growth. In this work, Zhang et al. concluded that the surgical paste with a faster 
in vitro release rate resulted in greater efficacy in vivo, as exhibited by tumor inhibition. 
 
3.6 Poly(Glycerol Monostearate -Caprolactone) Copolymer  
Films made out of poly(carbonate-co-ester) copolymers based on glycerol and ε-
caprolactone is another biomaterial device that has been investigated for localized cancer 
therapy. This polymer is very versatile as functional groups can be attached to it and thus, 
enabling it to be responsive to stimuli from the local environment (such as pH) and tailor its 
ability for different biomedical applications including drug delivery, targeting and 
imaging.[106] Another advantage of this copolymer is that it can be processed into different 
structures including fibers, particles and 3D constructs. 
 Liu et al. investigated the delivery of paclitaxel from poly(glycerol monostearate-co-
caprolactone) films for non-small-cell-lung cancer (NSCLC).[70] The polymeric films were 
prepared by first dissolving the polymer and drug in dichloromethane. The solution were then 
cast onto glass cover slips or collagen-based strips, depending on the assay or experiment that 
it will be used for. Liu et al. found that the implantation of the films following surgical 
resection was able to prevent the recurrence of local tumor without impairing wound healing. 
Poly(glycerol monostearate-co-caprolactone) films loaded with paclitaxel have also been 
tested in a recurrent sarcoma model.[68] The implanted device was found to reduce 
locoregional recurrence and improve overall survival compared to paclitaxel delivered by 
intravenous injection. In addition, Wolinsky et al. looked at using the same material to deliver 
a potent anticancer agent 10-hydroxycamptothecin (HCPT) to treat lung cancer.[69] They 
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concluded that the device was able to prevent local tumor growth compared to intravenous 
treatment or unloaded composites which developed rapid local tumors. 
 
4. Other Biomaterial-Based Implantable Therapies 
Besides the application of biomaterial-based implantable devices for the local delivery 
of chemotherapy as discussed in Section 3, these devices can also be used to deliver other 
cancer therapies. Concurrent therapies are a promising alternative approach to monotherapies. 
When optimally designed, they can result in a synergistic effect in combating cancer with 
reduced side effects and toxicity to surrounding cells. When combining two therapies, it is 
important to take overlapping toxicities into consideration.  
 
4.1. Chemotherapy or Anti-Angiogenic Agent Combined with Radiation 
Systemic chemotherapy in combination with radiotherapy is often used to treat 
different types of malignancies. As an alternative method of treatment, Ewend et al. 
investigated the local delivery of chemotherapy agents (i.e. BCNU, carboplatin or 
camptothecin) concurrently with external beam radiation (XRT) with p(CPP:SA) copolymer 
wafers.[7, 26] Unlike the treatment with local chemotherapy alone which allows higher doses of 
the drug to be tolerated by the patients, the combination of chemotherapy and radiation 
therapies needs to be done with lower concentrations of the drug to take into account the 
possible additive toxicity effect between the two treatments.[7] For their breast carcinoma 
metastases model, Ewend et al. found that the delivery of BCNU alone with p(CPP:SA) 
copolymer wafers was more effective than in combination with XRT which could be due to 
the higher dose (20% vs 10% loaded) that could be used for BCNU alone.[7] Ewend et al. also 
tested the combination in renal, colon, lung cancer and melanoma.[26] In the renal cancer and 
melanoma metastases models, BCNU and XRT together were more effective than XRT or 
BCNU alone. If chemotherapy is used without XRT, a higher dose of drug can be tolerated. 
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Thus, depending on the type of metastasis, some may benefit from the higher dose of 
chemotherapy alone or a combination of XRT and a lower dose of chemotherapy. Among 
chemotherapy drugs, alkylating agents such as temozolomide and nitrosourea (BCNU) are 
often combined with radiation,[107, 108] as they can synchronize cells in the G2M phase, 
resulting as radiosensitizers when applied with irradiation.[36] The local delivery of carmustine 
with whole-brain radiotherapy (WBRT) was investigated for adult patients who underwent 
craniotomy for a single brain metastasis.[66] It was concluded that the combinational treatment 
was safe and there was no local recurrence, but further study is required to assess the real 
effectiveness of the treatment. 
Besides chemotherapy agents, the potential of anti-angiogenic factors can also be 
enhanced by radiation therapy by increasing the sensitivity of tumor blood vessels to the anti-
angiogenic inhibition. Specifically, the sensitivity of blood vessels to vascular endothelial 
growth factor (VEGF) inhibition was augmented and led to growth delay of human tumor 
xenografts.[109] Vice versa, anti-angiogenic treatment can increase the effects of ionizing 
radiation by preventing the repair of endothelial cells that are damaged by radiation, and thus 
combining anti-angiogenic drugs with radiation is also a promising method of therapy.[110] 
Recently, Bow et al. showed that the combination of local delivery of an anti-angiogenic 
factor, minocycline using an implantable p(CPP:SA) wafer with radiotherapy resulted in 
139% and 289% increase in median survival compared to radiotherapy or minocycline 
polymer alone, respectively.[23] The delivery of an anti-angiogenic factor locally can 
potentiate the effect of radiotherapy. 
 
4.2. Anti-Angiogenic Agent Combined with Systemic Chemotherapy 
As for radiation therapy, chemotherapy can also augment the sensitivity of blood 
vessels to anti-angiogenic factors by increasing the sensitivity of tumor blood vessels to the 
anti-angiogenic inhibition.[109] Specifically, blood vessels sensitivity to VEGF inhibition can 
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be augmented which lead to growth delay of human tumor xenografts.[109, 111] Vice versa, anti-
angiogenic factors can improve the clinical response to chemotherapy. Although the activity 
of anti-angiogenic factors have been promising in patients suffering from different types of 
cancers, the benefits of current anti-angiogenic treatments by themselves on patient survival 
has been very modest as its often cytostatic rather than cytoreductive. Thus, there is a need for 
the combination of anti-angiogenic therapy with other available therapeutic advances. The 
anti-VEGF inhibitor bevacizumab (the first FDA approved anti-angiogenic drug), when 
combined with conventional chemotherapies has been shown to significantly increase overall 
survival or progression-free survival of patients with metastatic colorectal cancer, NSCLC 
and breast cancer.[112-114] A concern with concurrent delivery of other therapeutics with anti-
angiogenic factors is that the inhibition of blood vessel formation may result in impediment of 
the delivery of the other factors into the tumor. In contrast, as suggested by Mineli et al., the 
therapeutic factor may be entrapped in the tumor, increasing its bioavailability but the 
sequence and kinetics of delivery of the two different agents is vital for this to occur. [9] This 
window of opportunity is critical when combining with a cytotoxic agent such as a 
chemotherapy drug and the optimal dosing and scheduling of the anti-angiogenic agent is very 
vital. As stated elegantly by Ma et al., the net outcome of the combination therapy of an anti-
angiogenic and cytotoxic drug is the balance between (i) tumor cell starvation by the anti-
angiogenic drug, and (ii) decrease in cytotoxicity due to the availability of the cytotoxic drug 
in the tumor.[115] When the cytotoxic drug is the predominant factor as is usually the case 
because anti-angiogenic factors are not very beneficial alone,[8, 22] the efficacy of the cytotoxic 
drug may be compromised by the anti-angiogenic factor, instead of resulting in a synergistic 
effect. When net effect of the balance of new vessel formation and inhibition by drugs favors 
neovascularization, the tumor may still grow, but at a slower rate.[22] Interestingly, it has been 
shown that there is an improved clinical response when low dose of bevacizumab is combined 
with conventional chemotherapy compared to high dose of the drug.[116] This was also the 
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case with another anti-angiogenic factor, sunitinib where the interstitial fluid concentration of 
the chemotherapy agent temozolomide was increase when tumors were pretreated with a 
lower sunitinib concentration compared to the higher dose.[117] For monotherapy, chronic 
treatment of the anti-angiogenic factor with uninterrupted treatment may be beneficial. 
However, when combined with chemotherapy or other cytotoxic agents, a pre-treatment or 
concurrent delivery with a chemotherapy agent but in the earlier part of the treatment process 
would be more beneficial. 
Malignant gliomas has very extensive microvascular proliferation and are among the 
most vascular of solid tumors,[118, 119] and thus, anti-angiogenesis treatment may be an 
important therapy for this type of cancer. Weingart et al. used EVAc discs to administer an 
anti-angiogenic drug, minocycline (Brand name: Minocin), with or without systemic delivery 
of BCNU.[22] Minocycline as well as other tetracyclines have been long used as an antibiotic 
and have also been applied for the treatment of cancer. Weingart et al. found inhibition of 
growth and prolonged survival time when local minocycline was delivered at the time of rat 
intracranial 9L glioma tumor implantation or after resecting the tumor. However, local 
delivery of minocylcline with the EVAc discs did not increase survival time when treatment 
was performed 5 days after tumor implantation, which mimics the time when extensive 
vascular proliferation has occurred. Combining the local delivery of minocycline with 
systemic delivery of the chemotherapy drug, BCNU significantly extended survival time but 
not better than the systemic delivery of BCNU alone. Thus, this suggests that for malignant 
gliomas with substantially developed vascular supply, minocycline delivered locally by EVAc 
discs is not able to significantly inhibit tumor progression by itself. 
Besides BCNU, p(CPP:SA) wafers have also been used to deliver anti-angiogenic 
factors locally. Specifically, Pradilla et al. investigated the delivery of synthetic endostatin 
fragment (EF) from p(CPP:SA) wafers (10 mg in weight, 10%, 20%, 40% drug).[29] 
Endostatin is known to block matrix-metalloproteinase-2 (MMP-2) and inhibit endothelial 
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cell proliferation.[29] Recombinant endostatin protein is often employed as an anti-angiogenic 
agent; however, its use is limited due to the high production costs associated to it. Pradilla et 
al. found that EF can inhibit angiogenesis in vitro and in vivo. In a rat cornea micropocket 
angiogenesis assay, they saw that corneas treated with scaffolds loaded with EF had 
significantly lower angiogenesis index (AI) compared with corneas treated with empty 
scaffolds at Days 12, 15 and 20. As a single agent, EF was not able to extent the survival time, 
however, when combined with the chemotherapy drug BCNU, a synergistic effect in 
prolonging survival was observed. Moreover, p(CPP:SA) wafers have also been used to 
deliver the anti-angiogenic drug minocycline. As discussed above, Weingart et al. 
investigated the delivery of minocycline with the non-biodegradeble copolymer EVAc.[22] 
Based on the finding from their previous study, the same group moved forward and tested the 
delivery of this drug with the biodegradable polymer, p(CPP:SA) in an intracranial rat model 
with and without concurrent systemic delivery of BCNU.[8] The implantation of the 
minocycline wafer (3 mm diameter × 1 mm height, 10 mg in weight, 50% drug by weight) at 
the time of tumor implantation resulted in an 100% increase in long-term survival compared 
to untreated control. When implanted 5 days after tumor implantation, there was only a 
modest increase in median survival time, which suggests that minocycline delivery alone is 
only effective before the development of substantial vascular supply. When combined with 
systemic BCNU, the median survival time when implanted 5 days after tumor implantation 
increased by 82%, 121% and 200%, compared to systemic BCNU alone, minocycline wafer 
alone and no treatment, respectively.  
Frazier et al. also showed similar results, however using a biodegradable p(CPP:SA) 
wafer.[8] The treatment of intracranial tumors in rats with the local delivery of minocycline 
alone from these wafers only had a modest minimal effect compared to no treatment. 
However, when combined with the alkylating chemotherapy drug, BCNU, the median 
survival time was extended by 200%. This suggests that for minocycline to be therapeutically 
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effective, a prior critical reduction in the tumor mass by BCNU is needed. The results 
obtained by Weingart et al.[22] and Frazier et al.[8] suggests that local delivery of anti-
angiogenic alone may only be beneficial for resected tumor sites. When patients are 
diagnosed with malignant gliomas, extensive vascular proliferation has already occurred and 
thus for the treatment of these highly vascularize unresected tumors, concurrent delivery of a 
chemotherapy agent may be needed. 
Recently, Bow et al. investigated the combination of local delivery of anti-angiogenic 
factor, minocycline with oral chemotherapy (i.e. temozolomide) for glioma.[23] The delivery 
of the anti-angiogenic factor locally with a p(CPP:SA) wafer potentiated the effects of oral 
temozolomide. The combination resulted in a 38% and 53% increase in median survival 
compared with temozolomide or minocycline alone, respectively. Bow et al. concluded that 
the combination of local delivery of an anti-angiogenic factor (instead of systemically) with 
oral chemotherapy may be able to increase median survival of glioblastoma patients.  
Sengupta et al. developed an innovative nanoscale delivery system that allows the 
delivery of a cytotoxic chemotherapy agent, doxorubicin and an anti-angiogenic agent, 
combretastatin that they term as “nanocell”.[120] This material delivered systemically, was able 
to improve the therapeutic index and reduce untargeted toxicity. Doxorubicin was first 
conjugated to PLGA nanoparticle and the combretastatin was trapped within the PEGylated-
phospholipid block-copolymer envelope of the nanocell. The combretastatin is first released 
from the outer shell of the nanocell, causing a vascular shutdown and intra-tumoral trapping 
of the nanoparticles and this is followed by the release of the cytotoxic agent from the core of 
the nanocell. 
Anti-angiogenic chemotherapy drugs are chemotherapy agents that also have anti-
angiogenic properties such as paclitaxel, DC101 and cyclophosphamide. These type of agents 
have also been shown to act synergistically with direct anti-angiogenic drugs such as the 
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combination of the anti-angiogenic drug, DC101 with vinblastine,[121] and anti-angiogenic 
drug, CD105 with cyclophosphamide.[122]  
 
5. Future Directions 
 Besides the application of biomaterial-based implantable devices for mono-
chemotherapy and combinational therapy (i.e. local delivery of a chemotherapy or anti-
angiogenic agent combined with radiotherapy or local delivery of an anti-angiogenic agent 
combined with systemic chemotherapy), there are other promising innovative applications of 
these devices to combat cancer which are discussed below. 
 
5.1. Local Concurrent Delivery of Chemotherapy and Anti-Angiogenic Agent 
Anti-angiogenic therapy is generally less toxic and less lightly to result in resistance 
compared to chemotherapies making it beneficial to be used as an anti-neoplastic agent. 
However, the benefits of anti-angiogenic treatment alone on patient survival has been very 
modest, and thus, there is a need for the combination of anti-angiogenic therapy with other 
available therapeutic advances. So far, anti-angiogenic drugs have been delivered locally with 
the systemic delivery of a chemotherapy agent.[8, 22, 23, 29] Another option to this is to deliver 
both drugs locally, in the same implantable device where the release kinetics of the different 
drugs can be tailored by the material properties of the biomaterials. This will allow an 
increase in local bioavailability of both drugs and also avoid systemic toxicity of the drugs. 
 
5.2. Local Delivery of Poly-Chemotherapy 
Combination chemotherapy has been used widely as lower doses of each drug can be 
delivered to reduce cytotoxicity as well as decrease the occurrence of resistance. When 
designing a combinational chemotherapy regimen that will be effective synergistically with 
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low cytotoxicity and decreased chance of resistance, it is important to: (i) choose drugs that 
do not have overlapping toxicities, (ii) use agents that have different mechanism of action, 
and (iii) use drugs with proven activity as a monotherapy.[123] Current strategies for 
combinational therapy have been focused on systemic delivery. Local delivery of the different 
drug is an alternative method that should be considered to lower systemic toxicity and 
increase local concentration of the drugs.  
 
5.3. Gene Therapy as an Alternative to Drug Delivery 
The original objective of gene therapy is to deliver a gene which replaces a defective 
gene.[97] However, the field of gene therapy has evolved to encompass introducing a new gene 
that encodes a specific therapeutic protein to a defect site in order to alter or control the path 
of cellular action.[124] Researchers have successfully identified proteins for different 
therapeutic purposes such as cancer; however, shortcomings associated with delivering 
recombinant protein have led to the use of gene therapy as an alternative approach to deliver 
the gene that encodes the protein of interest. Compared to the delivery of proteins, gene 
therapy allows for a longer bioavailability of the growth factors as DNAs have longer half-
lives compared to proteins.[125] Furthermore, manufacturing these recombinant proteins are 
expensive and more difficult compared to manufacturing the genes that encode the growth 
factors. By using gene therapy, the proteins are synthesized in vivo, and as a result, the 
proteins can be delivered in a more biologically active form,[126] with more precise post-
translational modification and tertiary structure formation.[127, 128] Hicks et al. investigated the 
delivery of the genetic sequence of bevacizumab (Avastin), an anti-human VEGF monoclonal 
antibody using adeno-associated virus (AAV) for the treatment of GBM.[129] The delivery of 
the vector with nAAV inhibited angiogenesis, reduced tumor growth and increased median 
survival in mice. 
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There are many promising implantable biomaterial based devices that have been 
developed for non-cancer applications, such as tissue engineering. These devices are usually 
composite systems which are made out of a scaffold component and a gene delivery vector 
that can assist in efficiently delivering the gene of interest. These vectors can be viral vector 
such as adenovirus and lentivirus or non-viral gene delivery vectors such as polymeric or 
lipid-based gene delivery vectors. Unlike the delivery of protein or drugs, the incorporation of 
a delivery vector component is crucial in aiding in the successful delivery of DNA because of 
the highly negative charge of DNA. An example of such composites is a composite developed 
by Curtin et al. which is made out of a collagen scaffold and nano-hyoxyapatite (nHA) as a 
non-viral gene delivery vector to deliver plasmid DNA.[130] Another example is Saraf et al.’s 
electrospun PCL fiber mesh scaffolds which incorporates poly(ethylenimine)-hyaluronic acid 
(PEI-HA) as a non-viral gene delivery vector.[104] These and many more other gene delivery 
implantable biomaterial-based devices developed under aa tissue engineering approach, may 
be promising candidates to be repurposed for cancer therapy applications. 
 
5.4. Scaffolds for Cancer Immunotherapy 
Immunotherapy is another strategy that aims to fight cancer, and has recently been 
considered as the fourth anti-cancer treatment method alongside surgery, chemo- and radio-
therapy. The purpose of immunotherapy is to generate an effective and durable immune 
response against cancer cells. Immunotherapy strategies may act via either stimulating the 
intrinsic immune system and/or providing extrinsic immune system components, such as 
specific proteins to be targeted by the immune cells.[131] The main types of conventional 
immunotherapy for cancer include: (i) monoclonal antibodies, (ii) immune checkpoint 
inhibitors, and (iii) cancer vaccines. Despite the rapid advancements in this field, the success 
rate of current immuno-oncology is still marginal. To date, these therapies need cumbersome 
and expensive laboratory manipulations, which, however, have so far resulted in low homing 
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of ex vivo engineered cells in lymph nodes, thus suggesting that the present approaches should 
be synergized with other scientific areas to succeed in a broader population of cancer patients, 
with long-lasting disease eradication.[132] Consistent with this view, additional types of 
immunotherapies have been studied, which exploit biomaterial-based implantable scaffolds. 
Using a locally implanted delivery system can be a strategy to maximize the immune response 
at the targeted site. Some recent highlights combined immunotherapy with biomaterial 
devices in very different and intriguing ways.[133] So far, implantable biomaterials have been 
used as scaffolds for three main immunotherapy applications: (i) to transplant lymphocytes 
pre-engineered against the tumor, (ii) to generate vaccine sites, and (iii) to capture metastases. 
Transfusion of lymphocytes, also known as adoptive T cell therapy, belongs to 
personalized medicinal therapies. It can potentially increase antitumor immunity and vaccine 
efficacy, thus holding the promise for the treatment of many cancer types. However, a limited 
efficacy has been pointed out during the clinical trials, which has ultimately restricted these 
therapies due to cost justification. Most importantly, in 40% - 60% of cases, the lymphocytes 
were able neither to be efficiently delivered to the tumor sites nor to further expand within 
immunosuppressive tumor microenvironments.[134] To increase lymphocyte concentration and 
delivery in proximity of cancer lesions, biomaterial-based devices can be extremely effective 
as they can be implanted next to inoperable tumors, or in resectioned tumor areas to attack the 
cancer cells possibly remaining in the surroundings.  
Under this approach, Stephan et al. developed bioactive polymeric scaffolds for 
delivering and expanding tumor-reactive T cells.[135] These authors tested their strategy in a 
mouse breast resection model and in a multifocal ovarian cancer model, also checking its 
efficacy in tumor-reactive lymph nodes. Tumor-targeting engineered T cells were prepared 
and seeded on porous alginate hydrogels. Alginate is an anionic polysaccharide that is derived 
from brown seaweeds, which represents an interesting biopolymer as it is obtained from a 
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renewable source. A water-insoluble form of alginate is obtained by crosslinking with calcium 
chloride. Alginate hydrogels are very versatile biomaterials for medical purposes: they are 
used for tissue engineering, drug delivery and can be chemically or physically modified to 
adjust their properties.[136] Stephan et al. functionalized alginate scaffolds with lipid-coated 
microparticles conjugated to antibodies, which provided adhesion molecules and stimulatory 
factors enabling fast migration, sufficient expansion, and efficient release of T cells, as shown 
by in vitro assays, such as migration, release, cytotoxic activity, and cytokine expression by 
lymphocytes (Figure 5). In animal models, these implants effectively sustained tumor-
targeting T cells and efficiently triggered tumor regression compared to conventional adoptive 
T cell therapies. The platform developed by Stephan and colleagues may be versatile to 
provide reservoirs of other cells useful in immunotherapy, such as natural killer T cells, thus 
appearing as a useful method for localized cell delivery in the treatment of cancer. 
In addition to T cell release, scaffold systems have shown to have a great ability in 
tuning vaccination kinetics by recruiting/delivering cells from/to a target area. Dendritic cells 
(DCs) are key actors in triggering and regulating T cell mediated immunity, thus are 
promising targets for immunotherapy. Usually, sequences in pathogenic DNA, such as 
lipopolysaccharides and cytosine-guanosine (CpG) are able to activate DCs via binding to 
Toll-like receptors (TLRs). Thereafter, activated DCs diffuse to lymph nodes targeting 
specific activation and replication of T cells. When this mechanism is dysregulated, tumors 
develop and grow without an appropriate response by cytotoxic T-lymphocytes (CTLs). 
Cancer vaccines exploit patient-derived blood monocytes, as they can be easily turned into 
DCs ex vivo, activated, and infused back to the patients with the purpose to activate T cells to 
kill cancer cells. However, these systemic approaches for cancer vaccines have generally 
failed to generate a sufficient number of functional CTLs, needed to achieve a durable anti-
tumor immunity. 
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A remarkable approach focused on the design of implantable biomaterials that 
regulated cell biology at a distance via targeting or mimicking specific cellular 
microenvironments in which certain cell populations were able to grow and differentiate. One 
remarkable example consisted of generating DC vaccines on implanted scaffolds (Figure 
6).[137] This kind of device are designed to recruit and activate a sufficient number of DCs in 
order to further prime specific T cell response in lymphoid tissues. It is known that DNA 
plasmids encoding tissue-inductive proteins can be released from polymeric scaffolds leading 
to the transfection of large numbers of cells.[138] Polymeric scaffolds show the ability to attract 
and house host DCs via cytokine release, and to induce their activation upon exposure to 
danger signals and cancer antigens pre-loaded in the material. As a result, these systems can 
enhance DC homing to lymph nodes in remarkable numbers, which is ultimately expected to 
lead to specific and powerful anti-tumor immunity. To prove this concept, Ali et al. used a 
macroporous PLG scaffold loaded with both granulocyte macrophage colony-stimulating 
factor (GM-CSF) as an inflammatory signal, and cancer antigens (in the form of tumor 
lysates) to be released in a defined spatiotemporal manner within an in vivo melanoma 
model.[139] In particular, the authors exposed the mice to B16-F10 cells, which are highly 
aggressive and poorly immunogenic. The encapsulation efficiency of GM-CSF into PLG 
scaffolds via a high pressure CO2 foaming process was 54%. The release profile of these 
matrices was tuned to accomplish an effective diffusion of GM-CSF in the surrounding tissue 
area, which was ultimately able to recruit host DCs. The scaffold released 60% of the 
bioactive factor within the first 5 days, followed by slow and sustained release of bioactive 
GM-CSF over the next 10 days. PLG matrices loaded with 3 μg of GM-CSF were implanted 
subcutaneously in C57BL/6J mice. This system allowed about 106 DCs to be first recruited 
and differentiated, which is the number usually administered by ex vivo protocols. These 
materials were able to sustain even larger numbers of DCs over time. In this way, a specific 
and protective anti-tumor immunity was achieved, which gave rise to 90% survival of treated 
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animals compared to 100% death in control groups (Figure 7). Using the same copolymer and 
various combinations of GM-CSF as an inflammatory cytokine, poly(ethylenimine) cytosine-
phosphodiesterguanine oligodeoxynucleotide (PEI-CpG-ODN) solution as danger signal, and 
tumor lysates as antigen, Ali et al. also proved that the PLG scaffold was able to control the 
activation and in situ localization of diverse host DC subtypes, which ultimately primed 
powerful and sustained activation of CD8(+) CTL, while inhibiting immunoregulatory 
mechanisms.[140] The findings of this study highlighted that a minimum number of DCs 
(4.2∙106), allocating defined fractions of plasmacytoid DCs (pDCs) and CD8(+) DCs subtypes 
(1.2∙106 and 0.6∙106, respectively) is necessary to induce high immunoprotection, which 
ultimately resulted in 90% survival in a subsequent tumor event.  
In a subsequent study, Ali et al. tested different classes of adjuvants in PLG scaffolds 
to select the best combination that induced tumor protection, thus identifying DC subsets and 
cytokines critical for vaccine efficacy.[141] In particular, the authors showed that CD8(+) DCs, 
pDCs, interleukine-12 (IL-12), and G-CSF were of utmost importance to activate antitumor 
responses. Lately, this PLG scaffold system was also combined with immune checkpoint 
antibodies, antiCTLA-4 or antiPD-1, demonstrating to enhance CTL activity and induce the 
regression of melanoma (solid B16) cancer in mice.[142] 
To avoid surgery for biomaterial device implantation, Bencherif et al. developed an 
injectable shape-memory cryogel based on alginate, incorporating both GM-CSF and CpG-
ODN, that is able to attract and activate DCs, respectively.[143] This alginate scaffold was 
modified with covalently coupled RGD peptides to improve cancer cell adhesion via integrin 
binding, and was pre-loaded with irradiated B16-F10 melanoma cells (Figure 8). The 
underlying hypothesis of this study was that an injectable biomaterial-based vaccination is 
able to retain the pre-loaded cancer cells within the scaffold microenvironment, whereas 
allowing the resident DC to traffic and interact with the antigen-carrying tumor cells. The use 
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of homologous tumor cell/scaffold vaccination also aims at overcoming the high costs for 
extensive ex vivo genetic manipulation of patients’ tumor cells and the regulatory issues of 
conventional whole-tumor cell vaccination, which, in the end, turned out not to be 
counterbalanced by the scarce efficacy shown in phase 3 trials. The scaffold system of 
Bencherif et al. displayed good encapsulation efficiency of GM-CSF and CpG ODN, and a 
sustained release of these molecules in a month time period, thus ensuring a durable 
microenvironment conditioning. The tumor cell/scaffold construct induced DC maturation by 
creating a powerful immunogenic microenvironment that ultimately evoked a strong T-
effector cell response. 
 A key feature of biomaterial scaffolds for immunotherapy relies on the combination 
of specific chemokine concentration gradients to attract DCs and suitable pore features - wide 
enough and fully interconnected - to accommodate their trafficking into and out of the 
scaffold. These two characteristics were demonstrated to strongly interplay by testing DCs 
with a 3D scaffold model, microfabricated to have defined pore sizes and 100% 
interconnectivity and also incorporating the chemokine CCL19.[144] Specifically, the 3D 
architecture of the scaffolds remarkably affected cell chemotaxis depending on pore size, and 
the activation state of the cells also concurred to influence their migration inside the scaffold. 
This study led to the identification in microfabricated scaffolds of a 75 μm pore size that, in 
presence of a chemokine concentration gradient, was not hindering cell motility, thus 
appearing suitable for biomaterial-aided vaccination.  
One approach pursued by Kim et al. used injectable mesoporous silica to generate a 
vaccine site in a mouse model injected with lymphoma cells.[145] Silica crystals exhibit 
inflammatory properties that are sensed by the cytoplasmic receptor NALP3, thus inducing 
innate immune response. The silica rods were 88×4.5 μm2 in size and had 10.9 nm pores, 
supported a tumor antigen and, upon subcutaneous injection, randomly self-assembled in a 3D 
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macroporous structure, which spontaneously developed an active microenvironment for 
recruiting and activating host immune cells, while discouraging fibroblast infiltration (Figure 
9). Coexistence of pore classes belonging to such different sizes was hypothesized to concur 
to efficient enrolment and organization of immune cells. The high surface area of this scaffold 
permitted specific signaling molecules to be released, which ultimately modulated the activity 
of the recruited host immune cells, such as DCs and prime CD8(+) and CD4(+) T cells. This 
system generated strong humoral and cellular immune responses, which gave rise to 
prolonged survival time of treated animals, thus disclosing intriguing opportunities for 
implanted biomaterials to act as vaccine sites via inducing antigen-specific adaptive immune 
responses.  
The studies conducted by Ali, Bencherif, Kim and their coworkers all differ from 
Stephen’s, since the scaffolds were used with different approaches, the formers as vaccine 
sites for resident lymphocytes, whereby Stephen’s system was used for the delivery of ex vivo 
engineered tumor-reactive lymphocytes. In both approaches, the biomaterials played a 
primary role to trigger cellular reactions that ultimately promoted tumor immunotherapy.   
A former investigation of Hori et al. may collocate at a mid-way in between the above 
mentioned approaches, as their device was intended both for cell/molecule delivery and for 
inducing an immunoresponse. These authors delivered therapeutic DCs, proteins/cytokines or 
other immunoregulatory factors using alginate ‘self-gelling” hydrogels.[146] These hydrogels 
were implanted at peritumoral level through injection to ovalbumin (ova)-expressing B16F0 
murine melanoma tumor, therefore the tumor growth and recruitment of leukocytes were 
investigated.  B16-ova tumor cells were inoculated in mice and 7 or 14 days later they had 
received a peritumoral injection of empty or loaded self-gelling alginate matrices, as depicted 
in Figure 10. Hori et al. found that compared to systemic injection, interleukin-15 
superagonist (IL-15SA), IL-15SA-carrying alginate gels were able to concentrate the cytokine 
in the tumor site approximately 40-folds and suppress tumor growth for a week or more. They 
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also found that there was not a need to delivery DCs with the immune stimulatory factors, as 
the delivery of IL-15SA and TLR ligand CpG or two injections of IL-15SA alone were able to 
elicit comparable anti-tumor activity without the delivery of DCs. The local delivery of 
immunotherapy with the injectable alginate hydrogels was able to promote local immune 
response and limit the systemic side effects. 
There are different studies that investigated the delivery of a chemotherapy agent 
(ADR, BCNU or carboplatin) from an implantable scaffold with the local delivery of 
immunotherapy agents loaded in microspheres by injection.[27, 89] Development of implantable 
devices loaded with both the chemotherapy and immunotherapy agents in single implantable 
device may be a promising alternative if the release of the drugs, molecules and cells are 
properly controlled. Beside melanoma immunotherapy, which has been widely investigated in 
this decade, many other cancer types may benefit from localized immunotherapy combined 
with conventional chemotherapies or radiotherapies. In immunocompromised patients, such 
as for leukemia, in which the induced immunoresponse can be largely insufficient to fight 
cancer, a biomaterial-based approach could pre-stimulate the immune system by helping to 
reconstitute the hematopoietic cell niche before vaccination, and this is the subject of ongoing 
ambitious studies. 
In addition to their intriguing capabilities for tumor-localized drug and immune cell 
delivery/recruitment, biomaterial-scaffolds have shown other unexpected properties to fight 
cancer. One of them is the scaffold ability to attract metastatic cells in vivo as reported by 
Azarin et al.[147] By exploiting the local inflammatory response generated following the 
scaffold implantation, immune cells were attracted to the scaffold that further recruited 
circulating breast metastatic cells at the early onset of the metastatic process. A porous PLGA 
scaffold obtained via particle-leaching was used for this purpose (Figure 11). It was 
engineered with lentivirus for the chemokine CCL22 to enable the infiltration of immune cells 
that finally attracted metastatic cell infiltration through modulation of the local immune 
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microenvironment. The detection of cancer cells was revealed by changes in tissue 
nanoarchitecture via inverse spectroscopic optical coherence tomography. The ability of this 
scaffold to reduce tumor burden in metastatic sites of breast cancer may disclose new 
therapeutic tools to improve patient prognosis and survival. 
5.5 Polymer-Based Composites 
 Therapies that involve multiple drugs may require different release kinetics for each 
drug to be beneficial and result in a synergistic outcome. Especially for a therapy involving a 
chemotherapy and an anti-angiogenic drug, the outcome of the therapy will be different when 
one factor is given before the other. Past studies that have looked at delivering both a 
chemotherapy and an anti-angiogenic factor together, delivered the anti angiogenic factor 
locally with an implantable material, however, the chemotherapy drug was delivered 
systemically.[8, 22, 29] The delivery of both agents locally by embedding them in a single 
scaffold would not allow much control of the two different drugs. Thus, an implantable 
delivery system which will allow the tailoring of two different release kinetics is much needed. 
The incorporation of another component to the implantable delivery device, such as micro- 
and nano-particles, to result in a composite system can enable a better control of the different 
drugs. Micro- and nano-particles have already been widely used for cancer treatment 
systemically, as well as locally. Implantation or injection of particles at the site of interest will 
result in dispersion of the particles in a short amount of time. However, when incorporated 
inside the scaffold, the particles will only be release as the polymer of the scaffold erodes. 
Embedding the particles in a scaffold is a useful way to help control and prolong the release 
of the drug and further protect the drug from degradation, which will ultimately lead to its 
inactivation. Examples of such devices are reported by Patel et al.[148] and Young et al. [149] 
and are biomaterial-based implantable composites which incorporates protein-loaded (i.e. 
BMP-2 and VEGF) gelatin microparticles in poly(propylene fumarate) (PPF) scaffolds for 
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bone tissue engineering applications. As discussed in Section 5.3, delivery system for genes 
also require composite systems that incorporates a scaffold component with a gene delivery 
vector that can efficiently aid in the delivery of the plasmid DNA, siRNA or microRNA to the 
cells of interest. Jeon et al. have shown that the incorporation of plasmid DNA into 
composites of PLGA microspheres and an injectable PLGA scaffold resulted in prolonged 
released compared to the delivery of the plasmid DNA in the PLGA scaffold alone.[150] Many 
biomaterial-based implantable composites have been developed for the delivery of drugs,[151] 
proteins,[148, 149] and genes[152, 153] for other applications, such as tissue engineering. 
Implantable composite systems such as these may serve as potential candidates to be used for 
cancer therapy applications. 
 One example of implantable polymer composite system that has already been 
investigated for cancer is a halloysite (Hal)-nanocomposite hydrogel that was developed by 
Rao et al. for colon cancer drug delivery.[154] Hal nanotubes are made out of natural occurring 
aluminosilicates. This material can be obtained at a low cost and has good biocompatibility, 
thus appearing a promising material compared to carbon nanotubes.[155] Rao et al. loaded their 
drug of interested, 5-Fluorouracil (5-FU), an anticancer drug, inside the Hal nanotubes, as 
well as in the hydrogel network. The release of the drug could be sustained for a longer period 
of time compared to using the hydrogel on its own and thus, displaying the benefits of using a 
composite system. 
6. Conclusion 
Through biomaterial-based implantable devices, the local delivery of cancer 
therapeutic agents, which can overcome obstacles faced by systemic delivery, may result in a 
more successful outcome. As a consequence, advancements in treatment by the application of 
local delivery devices may allow the repurposing of drugs that may have previously failed 
with systemic treatment. Future development of biomaterial-based implantable devices should 
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focus on the local delivery of a combinational therapy instead of the delivery of one 
traditional method alone. When designing combinational therapies, several important 
parameters should be taken into account, such as the timing of combining these different 
strategies. A number of factors, including the drug concentration, exposure time and drug 
administration schedule, and sequence of delivery have to be carefully considered when 
designing a successful drug delivery systems. It is important to note that local delivery may be 
suitable for localized lesions, which will be benefited from a regional therapy; however, for 
tumors that are poorly localized and that have spread, an approach which combines local 
delivery and systemic delivery may be more appropriate. All in all, biomaterial-based 
implantable devices offer amazing versatile and tailorable approaches to fight cancer: they 
can deliver different drugs or proteins of interest locally with controlled modes, and/or serve 
as tissue engineering scaffolds for immune cell recruitment/activation/proliferation, thus 
representing a key weapon for next generation therapies. 
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Table 1. Biomaterials that have been investigated for local delivery 
 
Device Bioactive Factor 
Type of  
Bioactive 
Factor 
Type of Cancer Year Reference 
NON-BIODEGRADABLE 
Ethylene-vinyl acetate copolymer (EVAc) 
Cylinders BCNU chemotherapy glioma 1989 
Yang et 
al.[74] 
Discs 
Minocycline (with or 
without systemic 
BCNU) 
anti-angiogenic 
factor with 
systemic 
chemotherapy 
glioma 1995 
Weingart 
et al. [22] 
Rods Amsacrine chemotherapy glioma 1996 
Wahlberg 
et al.[21] 
Triangle 
shaped 
fragment
s 
Mitoxantrone chemotherapy glioma 2004 
Saini et 
al.[20] 
Pellets Cisplatin chemotherapy cervical cancer 2006 
Keskar et 
al.[19] 
BIODEGRADABLE 
Polyanhydride poly[bis(p-carboxy-phenoxy)propane-sebacic acid] copolymer 
(p(CPP:SA)) 
Wafers Paclitaxel chemotherapy glioma 1994 
Walter et 
al. [30] 
Wafers BCNU Gliadel chemotherapy glioma 1995 
Brem et 
al.[81] 
Wafers Carboplatin chemotherapy glioma 1996 
Olivi et al. 
[28] 
Wafers 
BCNU, arboplatin 
and camptothecin 
(with or without 
external beam 
radiotherapy) 
chemotherapy 
Intracranial 
metastases from 
lung, renal, 
colon cancer and 
melanoma 
1996 
Ewend et 
al. [26] 
Wafers 
BCNU, carboplatin 
and camptothecin 
chemotherapy 
Intracranial 
metastases from 
breast cancer 
1998 
Ewend et 
al. [26] 
Wafers Mitoxantrone chemotherapy glioma 2002 
DiMeco et 
al. [25] 
Wafers BCNU Gliadel chemotherapy glioma 2003 
Westpahl 
et al. [31] 
Wafers 
Minocycline (with or 
without systemic 
BCNU) 
anti-angiogenic 
factor with 
systemic 
chemotherapy 
glioma 2003 
Frazier et 
al. [8] 
Wafers Doxorubicin chemotherapy glioma 2005 Lesniak et 
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al. [86] 
Wafers 
Interleukin-2 and 
adriamycin 
immunotherapy 
and 
chemotherapy 
glioma 2005 
Hsu et al. 
[27] 
Wafers 
Genetically 
engineered tumor 
cells that produce IL-
2 with BCNU or 
carboplatin 
immunotherapy 
and 
chemotherapy 
glioma 1999 
Sampath 
et al.[88] 
Wafers 
Interleukin-2 and 
BCNU 
immunotherapy 
and 
chemotherapy 
glioma 2003 
Rhines et 
al.[89] 
Wafers 
Synthetic endostatin 
fragment (with or 
without systemic 
BCNU) 
anti-angiogenic 
factor with 
systemic 
chemotherapy 
glioma 2005 
Pradilla et 
al. [29] 
Wafers 
Minocycline (with or 
without systemic 
Temozolomide or 
radiotherapy) 
anti-angiogenic 
factor with 
systemic 
chemotherapy 
glioma 2014 
Bow et 
al.[23] 
Wafers 
Cancer-cell 
glycolytic inhibitors 
(3-bromopyruvate (3-
BrPA) and 
Dichloroacetate 
(DCA) (with or 
without 
temezolomide or 
radiotherapy) 
chemotherapy glioma 2015 
Wicks et 
al.[32] 
Fatty acid dimer – sebacic acid copolymer (FAD-SA) 
Disc 
4-
hydroperoxycyclopho
sphamide (4HC) 
chemotherapy glioma 1995 
Judy et al. 
[33] 
Poly(lactic-co-glycolic acid) copolymer (PLGA) 
Thin film 
5-[125I]iodo-2’-
deoxyuridine 
radiation glioma 2000 
Mairs et 
al. [35] 
Wafers BCNU chemotherapy glioma 2002 
Seong et 
al.[102] 
Wafers BCNU chemotherapy glioma 2005 
Lee et al. 
[34] 
Electrosp
un 
meshes 
Paclitaxel chemotherapy glioma 2006 
Xie et al. 
[38] 
Sheet Doxurubicin chemotherapy glioma 2006 
Manome 
et al.[36] 
Electrosp
un discs 
and 
sheets 
Paclitaxel chemotherapy glioma 2008 
Ranganath 
et al. [37] 
Scaffolds 
from 
Chemokine CCL22-
lentiviral vector 
immunotherapy breast cancer 2015 
Azarin et 
al.[147] 
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microsph
eres 
Macropor
ous 
matrix 
Granulocyte 
macrophage colony-
stimulating factor 
(GM-CSF) and tumor 
lysates  
immunotherapy melanoma 2009 
Ali et 
al.[139] 
Macropor
ous 
matrix 
Various combinations 
of an inflammatory 
cytokine, immune 
danger signal, and 
tumor lysates 
immunotherapy melanoma  2009 
Ali et 
al.[140] 
Macropor
ous 
matrix 
Tumor lysates, GM-
CSF  and various 
Toll-like receptor 
(TLR) agonists 
immunotherapy melanoma  2014 
Ali et 
al.[141] 
Macropor
ous 
matrix 
Tumor lysates, GM-
CSF and CpG-ODN, 
used in combination 
with immune 
checkpoint antibodies 
immunotherapy melanoma  2016 
Ali et 
al.[142] 
Poly(ε-caprolactone) (PCL) 
Surgical 
paste 
Paclitaxel chemotherapy 
Not designed for 
a specific type of 
cancer 
1996 
Winternitz 
et al.[105] 
Surgical 
paste 
(with or 
without 
MePEG) 
Bis(maltolato)oxovan
adium (BMOV) 
chemotherapy 
Not designed for 
a specific type of 
cancer: tested in 
vitro on colon, 
breast and non-
small-cell lung 
cancer human 
cell lines, in vivo 
on murine 
radiation-induce  
fibrosarcoma 
(RIF-1) tumor 
model 
1996 
Jackson et 
al. [39] 
Surgical 
paste 
(blends 
of low 
MW 
PDLLA:
PCL#) 
Paclitaxel chemotherapy 
Not designed for 
a specific type of 
cancer: tested in 
vivo on 
lymphoma cell 
tumor model 
1996 
Zhang et 
al. [40] 
Surgical 
paste 
Gelatin 
microparticles/ 
Paclitaxel 
chemotherapy 
Not designed for 
a specific type of 
cancer: tested in 
vivo on 
lymphoma cell 
tumor model 
1997 
Dordunoo 
et al.[41]  
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Poly(glycerol monostearate-co-caprolactone) 
Films 
10-
hydroxycamptothecin 
(HCPT) 
chemotherapy Lung cancer 2010 
Wolinsky 
et al. [69] 
Films Paclitaxel chemotherapy 
Non-small-cell 
lung cancer 
(NSCLC) 
2010 
Liu et al. 
[70] 
Films Paclitaxel chemotherapy sarcoma 2012 
Liu et al. 
[68] 
Alginate 
Injectable 
hydrogel 
Immune cells, 
proteins/cytokines or 
other 
immunoregulatory 
factors 
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Figure 1. Representative SEM images of lateral sections of an EVAc scaffold loaded with 
cisplatin at (A) low magnification (scale bar = 500 μm) and (B) higher magnification (scale 
bar = 25 μm) which show two clear phases. (C) Energy Dispersive X-Ray Spectroscopy 
(EDS) spectra at the two indicated locations indicated in the inset scanning electron, polymer 
matrix ( , I) and cisplatin crystals ( , II). Reproduced with permission.[19] 2006, Elsevier.  
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Figure 2. Photograph of the placement of GLIADEL wafers into a human brain following 
resection of a malignant glioma by lining 8 wafers on the walls of the tumor cavity. 
Reproduced with permission.[156] 2004, Nature Publishing Group. 
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Figure 3. Representative histological images of animal brain of control group and (B) 
doxorubicin loaded pCPP:SA scaffold group.  Arrow in A and B shows the presence of tumor 
cells and tissue necrosis, respectively. Reproduced with permission.[86] 2005, International 
Institute of Anticancer Research (IIAR). 
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Figure 4. Representative SEM images of paclitaxel-loaded PLGA microfiber film: (S1) non-
woven fabric, (S1a) before release and after 61-day release and paclitaxel-loaded PLGA 
nanofiber film: (S2) non-woven fabric, (S2a) before release and (S2b) after 61-day release. 
Reproduced with permission.[38] 2006, Springer. 
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Figure 5. Schematic of Stephen et al’s scaffold loaded with T cell in a tumor resection bed or 
inoperatable tumor site.  Stimulatory lipid-coated silica microspheres incorporated into porous 
alginate scaffolds trigger T cell expansion and result in the exit of the cells into surrounding 
tissue. Reproduced with permission.[135] 2015, Nature Publishing Group. 
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Figure 6. Schematic of an implantable biomaterial scaffolds which may mimic a vaccine site 
against an infection or tumor. The biomaterials contain both recruiting and programming 
factors for a cell population of interest, such as immature dendritic cells. This biomaterial acts 
as a niche by providing signals for cell differentiation and release towards the target organ, 
namely the lymph node, in which programmed dendritic cells finally activate the lymphocytes. 
Reproduced with permission.[137] 2009, Nature Publishing Group. 
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Figure 7. Results of Ali and coworkers’ experiment in melanoma cell infected mice testing 
implanted PLG scaffolds, mimicking cancer infections that allow for recruitment, 
proliferation and activation of DCs, which trigger T cells in lymph nodes ultimately attacking 
melanoma cells. (A) Pictures of lymph node biopsies of mice treated with matrices 
incorporating 10 μg CG-ODN and 3000 ng of GM-CSF, versus untreated controls. (B) 
Comparison of survival time in mice treated with controls (blank scaffolds), tumor lysate + 
100 μg CpG-ODN, tumor lysate + 3000 ng GM-CSF + 10 μg CpG-ODN, and tumor lysate + 
3000 ng GM-CSF + 100 μg CpG-ODN. The mice were immunized using a cell-based vaccine. 
Reproduced with permission.[139] 2009, Nature Publishing Group. 
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Figure 8. Alginate sponge loaded with irradiated B16-F10 cells as a vaccine strategy for 
melanoma. (a) Schematic of scaffold/cell construct preparation. The alginate matrix contains 
a TLR9-based immune adjuvant (CpG ODN), a cytockine adjuvant (GM-CSF) and RGD 
sequences. (b, c) SEM micrographs showing the scaffold: (b) top surface and (c) morphology, 
pores and pore interconnectivity in cross-section. (d, e) Laser scanning confocal microscopy 
images showing B16-F10 cells immobilized on the scaffold after 6 h. Actin filaments are 
imaged in green, cell nuclei in blue and polymer in red: (d) 2D micrograph and (e) 3D 
reconstruction. Reproduced with permission.[143] 2015, Nature Publishing Group. 
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Figure 9. Schematic of the spontaneous assembly of mesoporous silica rods (MSRs) in vivo. 
MSRs dispersed in PBS are injected subcutaneously into mice. In situ spontaneous assemble 
of MSRs occurs after PBS diffusion from the vaccine site, resulting in the formation of 3D 
interparticle macropores. Recruited host cells are exposed to the inflammatory signals which 
then migrate from the device and interact with other immune cells. Reproduced with 
permission.[145] 2015, Nature Publishing Group. 
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Figure 10. Schematic of the local immunotherapy system by Hori et al. B16-ova tumor cells 
were inoculated into C57B1/6 mice and the peritumoral injection of empty or loaded self-
gelling (loaded with immune cells, proteins/cytokines or other immunoregulatory factors) 
alginate matrices 7 or 14 days later. After 14-21 days, the immune response and tumor growth 
were determined. Reproduced with permission.[146] 2009, Elsevier. 
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Figure 11. Representative bioluminescence and H&E stained histological images of 
peritoneal fat pads removed 28 days after tumor inoculation. Fat pads implanted with PLG 
scaffold resulted in the recruitment of metastatic cells (a,d) whereas sites without scaffolds 
did not accumulate tumor cells (b,e). The white circle indicates metastatic cluster. Figure c 
represent H&E staining of a primary tumor. Scale bars in c,d,e are 100 μm. Reproduced with 
permission.[147] 2015, Nature Publishing Group. 
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